Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Oct:127:107115.
doi: 10.1016/j.parkreldis.2024.107115. Epub 2024 Aug 28.

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations

Avner Thaler  1 , Saar Anis  2 , Penina Ponger  3 , Tsviya Fay-Karmon  4 , Vered Livneh  3 , Achinoam Faust-Socher  3 , Lior Greenbaum  5 , Johnathan Reiner  6 , Ariela Hilel  7 , Hertzel Shabtai  7 , Roy N Alcalay  8 , Ruth Djaldetti  6 , Sharon Hassin-Baer  4 , Adi Ezra  7 , Anat Mirelman  9 , Nir Giladi  10 , Tanya Gurevich  10
Affiliations
Observational Study

Levodopa-carbidopa intestinal gel for advanced Parkinson's disease: Impact of LRRK2 and GBA1 mutations

Avner Thaler et al. Parkinsonism Relat Disord. 2024 Oct.

Abstract

Background: Advanced Parkinson's disease (PD) can be treated with Levodopa-Carbidopa Intestinal Gel (LCIG).

Objective: To compare descriptive data of LCIG treatment in GBA1-PD and LRRK2-PD.

Methods: This multicenter retrospective study compared clinical data obtained from electronic medical records of PD patients treated with LCIG. Patients were grouped based on their genetic status.

Results: Fifty-two iPD, 15 LRRK2-PD and 23 GBA1-PD were included in this study. No difference in daily dose of LCIG or levodopa equivalent daily dose were detected. GBA1-PD had significantly shorter disease duration at LCIG initiation (p = 0.01) and experienced more hallucinations (p = 0.03) compared with LRRK2-PD and iPD. LRRK2-PD and iPD had significantly longer duration of LCIG treatment compared with GBA1-PD (p < 0.01).

Conclusion: Overall, LCIG treatment was well tolerated in LRRK2-PD and GBA1-PD. GBA1-PD required LCIG earlier in their course of their disease and had higher frequencies of hallucinations during treatment, attesting to a more severe disease course.

Keywords: GBA1; Levodopa-carbidopa intestinal gel; Parkinson's disease LRRK2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

LinkOut - more resources